[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"immunosuppressive-treatment\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:immunosuppressive-treatment":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100593730","phase-2-dose-attenuated-ist-and-hetrombopag-in-elderly-65-years-patients-with-severe-aplastic-anemia-100593730",false,"NCT07010237","Dose-attenuated IST and Hetrombopag in Elderly (≥65 Years) Patients With Severe Aplastic Anemia","Dose-attenuated IST and Hetrombopag in the Treatment of Elderly (≥65 Years) Patients With Very Severe\u002FSevere Aplastic Anemia: A Single-Center, Single-Arm, Phase IIB Clinical Study on Efficacy and Safety","Inclusion Criteria:\n\n* Clinical diagnosis of VSAA\u002FSAA.\n* Age ≥65 years.\n* Completion of all screening assessments.\n* Must be able to swallow tablets.\n* Signed informed consent (by patient or legal guardian if patient is incapacitated).\n\nExclusion Criteria:\n\n* Clonal cytogenetic abnormalities (excluding isolated -Y or +8).\n* Prior treatment with ATG\u002Fhigh-dose cyclophosphamide.\n* Prior cyclosporine\u002Ftacrolimus use \\>12 months.\n* Prior TPO-RA therapy \\>3 months.\n* Uncontrolled malignancies or conditions contraindicating ATG.\n* Severe organ dysfunction (e.g., creatinine ≥177 μmol\u002FL).\n* Investigator judgment of unsuitability.","ALL","65 Years",{"count":19,"type":20},65,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This is a prospetive,Single-Center, Single-Arm, Phase IIB Clinical Study.This study aims to evaluate the efficacy and safety of dose-attenuated IST combined with Hetrombopag in elderly patients (≥65 years) with VSAA\u002FSAA.",[26,27,28],"Sever Aplastic Anaemia","Elderly (People Aged 65 or More)","Immunosuppressive Treatment","RECRUITING","2025-06-05",{"date":32,"type":33},"2025-06-08","ACTUAL",{"date":35,"type":33},"2025-02-01",{"date":37,"type":20},"2029-07-01",{"name":39,"class":40},"Institute of Hematology & Blood Diseases Hospital, China","OTHER"]